Senate Finance Committee Investigates Medical Societies’ Financial Ties to Pharma

Are medical societies compromised by pharma funding? The government launches a new probe to find out.

When Merck and Schering-Plough released data from a clinical trial of cholesterol medication Vytorin showing that it worked no better than a much cheaper generic, the companies were widely accused in the media of deliberately delaying the release of the findings for 20 months in order to boost profits — prompting the U.S. Senate Finance Committee to investigate. The result: the SFC has widened its inquiry into pharmaceutical industry funding, including CME grants, to see if these monies are b

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Already a member? .

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish